Stock listing

NASDAQ:FDMT 4D Molecular Therapeutics, Inc. Stock

Home listing (NASDAQ) of 4D Molecular Therapeutics, Inc.

Follow 4D Molecular Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:FDMT

$10.23 USD -0.23 (-2.2%)

Close on Nov 20, 2026

Past year -1.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$10.11 – $10.94 USDNov 20, 2026
Volume
690,941 sharesNov 20, 2026
Market cap
$565.1M USDAt the close on Nov 20, 2026 · price × 55.24M shares outstanding
52-week range
$6.96 – $16.93 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$13.13M USDMedian day 897,223 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
4D Molecular Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:FDMT · Home$10.23 USD-0.23 (-2.2%)690,941$10.36$10.94$10.11$10.46Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:FDMT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$10.23-0.23-2.2%$10.36$10.94$10.11690,941
$10.46-0.33-3.1%$10.77$10.99$10.30679,298
$10.79-0.50-4.4%$11.33$11.49$10.54813,812
$11.29-0.94-7.7%$12.25$12.34$11.22968,930
$12.23+0.115+0.9%$11.66$12.37$10.98813,801
$12.12-0.875-6.7%$12.59$12.86$12.05897,223
$12.99+0.53+4.3%$12.48$13.03$12.38837,170
$12.46-0.02-0.2%$12.43$12.76$12.151,075,502
$12.48+0.23+1.9%$12.42$12.71$12.15879,758
$12.25+1.00+8.9%$11.46$12.57$11.28993,257
$11.25-1.03-8.4%$12.11$12.11$11.161,598,595
$12.28+0.33+2.8%$12.36$12.42$11.55764,654
$11.95+0.58+5.1%$11.52$12.08$11.46740,402
$11.37-0.53-4.5%$11.88$12.06$11.16734,781
$11.90-0.88-6.9%$12.49$12.88$11.74683,476
$12.78-0.15-1.2%$13.00$13.46$12.57848,889
$12.93+0.97+8.1%$11.89$12.96$11.731,189,747
$11.96+0.93+8.4%$10.96$11.99$10.751,134,654
$11.03+0.23+2.1%$10.74$11.29$10.621,084,577
$10.80-1.05-8.9%$11.74$11.75$10.68996,140
$11.85-0.77-6.1%$12.60$13.12$11.681,354,686
$12.62-0.48-3.7%$13.12$13.45$12.612,019,208
$13.10+0.81+6.6%$12.29$13.39$12.29725,371
$12.29+0.15+1.2%$12.36$12.68$12.21855,679
$12.14-0.73-5.7%$12.84$12.84$12.00794,500
$12.87+0.67+5.5%$12.30$13.01$12.04787,600
$12.20-0.16-1.3%$12.18$12.58$11.99633,000
$12.36-0.64-4.9%$12.91$12.91$12.25991,700
$13.00-0.33-2.5%$13.30$13.47$12.86835,800
$13.33+0.63+5.0%$12.70$13.85$12.55867,900
$12.70+0.11+0.9%$12.42$12.74$12.12970,800
$12.59+0.03+0.2%$12.36$12.92$12.19603,600
$12.56-0.36-2.8%$12.64$13.02$12.301,170,900
$12.92-0.75-5.5%$13.86$13.86$12.612,110,300
$13.67-0.17-1.2%$14.12$14.14$13.601,036,900
$13.84-0.47-3.3%$14.23$14.58$13.80655,500
$14.31-0.18-1.2%$14.76$14.83$14.081,037,100
$14.49-0.07-0.5%$14.70$14.97$13.941,376,000
$14.56+0.09+0.6%$14.36$14.82$13.921,557,400
$14.47-0.24-1.6%$14.78$14.82$14.031,018,000
$14.71-0.29-1.9%$14.81$14.98$13.561,767,900
$15.00-0.88-5.5%$15.97$15.97$14.681,465,500
$15.88+0.64+4.2%$15.21$16.23$15.13936,600
$15.24+0.02+0.1%$15.57$15.70$14.68699,100
$15.22+0.54+3.7%$15.12$15.69$14.781,787,500
$14.68+0.92+6.7%$13.93$14.87$13.93930,600
$13.76+0.13+1.0%$13.65$14.20$13.55819,600
$13.63-0.13-0.9%$13.95$13.95$13.18552,000
$13.76+0.59+4.5%$13.64$14.19$13.43977,200
$13.17-0.32-2.4%$13.69$14.02$12.94481,100
$13.49-0.69-4.9%$13.88$14.02$13.40566,100
$14.18-0.45-3.1%$14.44$14.50$14.09493,800
$14.63-0.34-2.3%$14.57$15.29$14.13542,000
$14.97+0.27+1.8%$14.50$15.00$14.33420,600
$14.70-0.24-1.6%$14.94$14.94$14.28782,400
$14.94+0.59+4.1%$14.40$15.13$14.081,035,900
$14.35+0.24+1.7%$13.94$14.85$13.80708,000
$14.11-0.56-3.8%$14.49$14.60$13.671,404,200
$14.67-0.24-1.6%$14.92$15.00$14.201,101,300
$14.91-0.65-4.2%$15.44$15.77$14.82717,600
$15.56-0.16-1.0%$15.50$15.67$15.04717,900
$15.72+0.33+2.1%$15.69$16.34$15.42919,118
$15.39-0.44-2.8%$15.68$15.83$14.351,474,743
$15.83-0.27-1.7%$16.32$16.91$15.33918,700
$16.10-0.66-3.9%$16.50$16.71$15.631,630,800
Ticker
NASDAQ:FDMT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All 4D Molecular Therapeutics, Inc. news

4D Molecular Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 131 in all · newest Nov 13, 2026 · oldest 2020
Decks
24 decks · latest September 2026

Where 4D Molecular Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:FDMT · Home listing · This pageNASDAQUnited StatesUSD
BOATS:FDMTBOATSUnited StatesUSD

Valuation

EV/sales 2.9× against a median of 47.1×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$277.8M USD
P/E
Loss
EV/sales
2.9×
EV/EBITDA
Negative EBITDA
Price/book
1.7×
Gross margin
4.8%
Operating margin
−226.0%
Net margin
−208.6%
Debt to equity
0.1×
Beta vs S&P 500
1.75

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
4D Molecular Therapeutics, Inc. · NASDAQ:FDMTUS$565.1MUS$277.8Mn/a2.9×n/a1.7×−208.6%0.1×1.75
Design Therapeutics, Inc. · NASDAQ:DSGNUS$577.6MUS$371.5Mn/an/an/a2.9×n/a0.0×1.29
Cullinan Therapeutics, Inc. · NASDAQ:CGEMUS$577.1MUS$289.6Mn/an/an/a2.0×n/a0.0×1.45
Immix Biopharma, Inc. · NASDAQ:IMMXUS$577.0MUS$241.7Mn/an/an/a1.7×n/a0.0×1.60
Entera Bio Ltd. · NASDAQ:ENTXUS$574.8MUS$308.9Mn/an/an/a2.1×n/a0.0×0.76
DBV Technologies SA · EURONEXT:DBVUS$571.8MUS$430.7Mn/a47.1×n/a3.9×n/a0.1×n/a
Ascletis Pharma, Inc. · HKEX:1672US$571.3MUS$232.4Mn/a765×n/a1.7×n/a0.0×n/a
Bicara Therapeutics Inc. · NASDAQ:BCAXUS$560.3MUS$118.8Mn/an/an/a1.4×n/a0.0×1.37
Lepu Biopharma Co. Ltd. Class H · HKEX:2157US$554.8MUS$613.4M14.6×4.5×22.9×2.6×28.0%0.8×n/a
Aclaris Therapeutics, Inc. · NASDAQ:ACRSUS$545.6MUS$431.3Mn/a67.4×n/a3.3×n/a0.0×1.42
ArriVent BioPharma, Inc. · NASDAQ:AVBPUS$544.1MUS$151.2Mn/a30.2×n/a1.4×n/a0.0×1.18
Median of the othersUS$571.6MUS$299.3M14.6×47.1×22.9×2.1×28.0%0.0×1.37

Forecasts

9 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
28.09 USD · Analysts' mean
EPS, year to Dec 2026
-4.14 · 10 analysts
Revenue, year to Dec 2026
13.25M · 10 analysts

Team and board

Officers

OfficerRole
David KirnChief Executive Officer, President, and Co-Founder
Kristian HumerChief Financial Officer
Scott BizilyChief Legal Officer
Chris SimmsChief Commercial & Business Officer
Dhaval DesaiChief Development Officer
John F. MilliganExecutive Chairman
Julie ClarkChief Medical Officer
Katy BarglowChief Technical Officer
Kim MaplestoneChief Clinical Operations Officer
Theresa JankeChief of Staff, Co-Founder

Board

DirectorRole
John F. MilliganExecutive Chairman
Charles TheuerDirector
Glenn P. SblendorioBoard Member
Jacob ChackoDirector
Nancy Miller-RichBoard Member
Shawn TomaselloDirector
Susannah GrayDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close+0.9%
Q2 2026Aug 13, 2026 · After close+4.6%
Q1 2026May 7, 2026 · After close+2.1%
Q4 2025Feb 27, 2026−3.4%
Q3 2025Nov 10, 2025 · Before open−3.1%
Q2 2025Aug 11, 2025 · Before open−1.8%
Q1 2025May 8, 2025 · After close−4.9%
Q4 2024Feb 26, 2025 · Before open+5.7%
Q3 2024Nov 13, 2024 · After close+4.0%
Q2 2024Aug 8, 2024 · After close+0.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close+0.2%
Q4 2023Feb 29, 2024 · After close+4.8%
Q3 2023Nov 9, 2023 · After close+5.2%
Q2 2023Aug 9, 2023 · After close−2.3%
Q1 2023May 10, 2023 · After close−4.3%
Q4 2022Mar 15, 2023 · After close+5.7%
Q3 2022Nov 8, 2022 · After close+6.4%
Q2 2022Aug 11, 2022 · After close−8.3%
Q1 2022May 12, 2022 · After close−4.3%
Q4 2021Mar 28, 2022 · After close+6.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck60 slidesSeptember 2026
Technical Presentation (May 2026)Technical12 slidesMay 2026
J.P. Morgan Healthcare Conference 2026Conference39 slidesJanuary 2026
Technical Presentation (December 2025)Technical65 slidesDec 17, 2025
Technical Presentation (July 2025)Technical12 slidesJuly 2025
Bank of America 2025 Healthcare ConferenceConference22 slidesMay 2025
Technical Presentation (January 2025)Technical16 slidesJan 10, 2025
Technical Presentation (2025)Technical16 slides2025
EURETINA 2024Conference17 slidesSeptember 2024
Retina Society 2024Conference14 slidesSeptember 2024
All 24 decks
DeckKindSlidesDate
Investor Presentation (August 2024)Investor deck77 slidesAugust 2024
ASRS 2024Conference13 slidesJul 15, 2024
Clinical Trials at the Summit (June 2024)Conference10 slidesJun 6, 2024
47th European Cystic Fibrosis Conference (ECFS 2024)Conference22 slidesJun 5, 2024
Technical Presentation (April 2024)Technical15 slidesApr 20, 2024
Gene Therapy for Ophthalmic Disorders Summit 2023Conference25 slidesNov 28, 2023
Fact Sheet (September 2023)Fact sheet2 slidesSep 22, 2023
Technical Presentation (July 2023)Technical15 slidesJuly 2023
ASGCT Symposium 2023Conference33 slidesMay 18, 2023
ARVO 2023Conference17 slidesApril 2023
Investor Presentation (January 2022)Investor deck35 slidesJan 11, 2022
Technical Presentation (2021)Technical9 slides2021
Technical Presentation (2021)Technical17 slides2021
ASGCT 2021Conference14 slides2021

Open Decks

Financings

RaiseDate
Public offering of equity
Closed: US$93M raised · US$10.51 a share · Leerink Partners +3
Dealers: Leerink Partners (co-lead), Evercore ISI (co-lead), Cantor (co-lead), RBC Capital Markets
Use of proceeds: Fund planned operations into 2H 2028, including a planned 4D-150 Phase 3 trial in diabetic macular edema
Nov 10, 2025
Strategic investment of 4DMT equity
Tranche closed: US$7.5M raised
Buyers: Cystic Fibrosis Foundation (up to $11 million in 4DMT equity in two tranches; first tranche of $7.5 million closed)
Use of proceeds: Accelerate development of 4D-710 for cystic fibrosis: second dosing in Phase 1, advancement into Phase 2, and Phase 3 readiness
Oct 13, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$23.00 a share on Dec 10, 2020.

Price
US$23.00 a share
Shares offered
8,400,000 shares of common stock
Offering size
US$193.2 million
Underwriters' option
Up to 1,260,000 more shares
Underwriters
Goldman Sachs & Co. LLC, BofA Securities, Evercore ISI · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceOct 14, 2020
Filed publiclyNov 17, 2020
Amended twiceNewest Dec 10, 2020
Shares registered with an exchangeDec 8, 2020
Declared effective by the SECDec 10, 2020
Final prospectus, with the priceDec 14, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Dec 14, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue85.2M37.0K20.7M3.13M18.0M13.6M6.99M14.1M5.79M
Cost of revenue7.63M141.3M97.1M3.88M3.02M53.0M38.7M18.4M13.6M
Gross profit77.6M-141.3M-76.4M3.13M18.0M-39.4M-31.7M-4.23M-7.78M
Research and development195.7M141.3M97.1M80.3M61.4M53.0M38.7M18.4M13.6M
Selling, general and administrative49.1M46.6M36.5M32.9M28.0M17.2M13.9M6.17M3.49M
Operating income-159.5M-187.8M-112.9M-110.0M-71.3M-56.7M-50.8M-10.4M-11.3M
Depreciation and amortization4.69M4.65M4.20M2.40M1.52M1.44M1.00M697.0K626.0K
EBITDA-154.9M-183.2M-108.7M-107.6M-69.8M-55.2M-49.8M-9.70M-10.6M
Interest expense6.42M3.04M152.0K000
Income before tax-140.1M-160.9M-100.8M-107.5M-71.3M-56.7M-49.3M-9.55M-11.2M
Income tax0000003.63M848.0K-89.0K
Net income-140.1M-160.9M-100.8M-107.5M-71.3M-56.7M-49.3M-9.55M-11.2M
Earnings per share, basic-2.42-2.98-2.58-3.32-2.57-8.82-9.59-0.76-0.76
Earnings per share, diluted-2.42-2.98-2.58-3.32-2.57-8.82-9.59

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents60.2M149.3M249.1M52.4M153.0M276.7M49.7M91.8M23.9M
Short-term investments342.4M275.5M39.1M161.2M94.8M0
Receivables047.0K1.49M978.0K1.12M321.0K
Inventory-5.79M-8.50M1
Current assets413.1M434.9M296.6M220.5M256.3M282.7M52.5M94.1M24.5M
Property, plant and equipment14.9M19.5M20.1M22.3M14.4M5.07M5.05M2.47M2.72M
Total assets566.7M560.4M339.9M261.8M353.5M288.3M58.2M97.0M27.3M
Accounts payable11.2M4.39M3.52M3.32M4.76M1.79M1.74M954.0K460.0K
Current liabilities44.0M29.1M19.0M15.7M16.3M16.7M13.0M8.05M5.91M
Long-term debt0
Total debt024.6M14.7M16.1M16.4M
Total liabilities61.0M49.8M32.1M30.5M34.4M31.9M28.2M124.6M46.9M
Shareholders' equity505.7M510.6M307.8M231.3M319.1M256.4M-73.0M-27.6M-19.6M
Shares outstanding57.6M45.8M43.1M32.6M32.2M26.7M5.18M12.5M14.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-109.1M-134.6M-75.8M-86.7M-69.1M-50.9M-36.7M-16.3M8.24M
Capital spending-536.0K-3.79M-2.77M-11.5M-9.11M-1.00M-3.20M-414.0K-573.0K
Free cash flow-109.6M-138.4M-78.6M-98.2M-78.2M-51.9M-39.9M-16.7M7.66M
Cash from investing-93.0M-302.4M115.7M-17.1M-172.7M-1.00M-3.20M-414.0K7.67M
Cash from financing113.0M337.3M156.8M3.08M118.1M279.0M-2.19M84.6M16.0K
Share buybacks7.50M-468.0K114.7M-278.1M-2.27M
Change in cash-89.1M-99.8M196.8M-100.7M-123.7M227.1M-42.1M67.9M15.9M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
144 · Notice of proposed saleOct 5, 2026Other filingsSEC
8-K · Current reportSep 28, 2026Current reportSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 16, 2026Insider tradeSEC
144 · Notice of proposed saleSep 14, 2026Other filingsSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
144 · Notice of proposed saleAug 4, 2026Other filingsSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
8-K · Current reportJul 20, 2026Current reportSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
144 · Notice of proposed saleJul 10, 2026Other filingsSEC
144 · Notice of proposed saleJul 9, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
8-K · Current reportJun 29, 2026Material contractSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
8-K · Current reportJun 22, 2026Meeting outcomeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveMay 14, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2026Big-stake noticeSEC
CORRESP · Letter to the SECMay 11, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 8, 2026Other filingsSEC
S-3 · Registration statementMay 7, 2026Offer documentSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 7, 2026Big-stake noticeSEC
8-K · Current reportMar 30, 2026Management or board changeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 18, 2026Offer documentSEC
10-K · Annual reportMar 18, 2026Annual reportSEC
8-K · Current reportMar 18, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 9, 2026Big-stake noticeSEC
8-K · Current reportJan 26, 2026FinancingSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
8-K · Current reportJan 7, 2026ResultsSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 11, 2025Insider tradeSEC
8-K · Current reportDec 10, 2025Current reportSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
8-K · Current reportNov 17, 2025Management or board changeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
8-K · Current reportNov 7, 2025Current reportSEC
424B5 · ProspectusNov 6, 2025Offer documentSEC
8-K · Current reportNov 6, 2025ResultsSEC
8-K · Current reportOct 31, 2025Material contractSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
144 · Notice of proposed saleOct 24, 2025Other filingsSEC
4 · Change in ownershipOct 20, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 20, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 17, 2025Big-stake noticeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2025Insider tradeSEC
8-K · Current reportOct 2, 2025Management or board changeSEC
4 · Change in ownershipSep 26, 2025Insider tradeSEC
144 · Notice of proposed saleSep 23, 2025Other filingsSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportAug 11, 2025ResultsSEC
8-K · Current reportJul 2, 2025Management or board changeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
8-K · Current reportJun 20, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansMay 8, 2025Offer documentSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveMar 25, 2025Other filingsSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
POS AM · Amendment to an effective registrationFeb 28, 2025Offer documentSEC
S-8 · Registration statement for employee plansFeb 28, 2025Offer documentSEC
10-K · Annual reportFeb 28, 2025Annual reportSEC
8-K · Current reportFeb 28, 2025ResultsSEC
POSASRFeb 28, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2025Big-stake noticeSEC
8-K · Current reportFeb 10, 2025Current reportSEC
8-K · Current reportJan 10, 2025ResultsSEC
8-K · Current reportDec 11, 2024FinancingSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedDec 6, 2024Big-stake noticeSEC
3 · Initial statement of ownershipNov 25, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 15, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 8, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 6, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 4, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 21, 2024Big-stake noticeSEC
4 · Change in ownershipSep 18, 2024Insider tradeSEC
8-K · Current reportSep 18, 2024Current reportSEC
4 · Change in ownershipAug 21, 2024Insider tradeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
3 · Initial statement of ownershipAug 1, 2024Insider tradeSEC
8-K · Current reportJul 23, 2024Current reportSEC
4 · Change in ownershipJul 18, 2024Insider tradeSEC
8-K · Current reportJul 17, 2024Current reportSEC
4 · Change in ownershipJul 15, 2024Insider tradeSEC
4 · Change in ownershipJul 12, 2024Insider tradeSEC
144 · Notice of proposed saleJul 10, 2024Other filingsSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
144 · Notice of proposed saleJul 1, 2024Other filingsSEC
4 · Change in ownershipJun 26, 2024Insider tradeSEC
144/A · Notice of proposed sale, amendedJun 25, 2024Other filingsSEC
144 · Notice of proposed saleJun 24, 2024Other filingsSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
8-K · Current reportJun 7, 2024Material contractSEC
424B5 · ProspectusJun 7, 2024Offer documentSEC
8-K · Current reportMay 24, 2024Meeting outcomeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
8-K · Current reportMay 9, 2024ResultsSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
4 · Change in ownershipApr 18, 2024Insider tradeSEC
ARS · Annual report to shareholdersApr 10, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 10, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 10, 2024Meeting noticeSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
144 · Notice of proposed saleApr 1, 2024Other filingsSEC
4 · Change in ownershipMar 29, 2024Insider tradeSEC
4 · Change in ownershipMar 20, 2024Insider tradeSEC
4 · Change in ownershipFeb 29, 2024Insider tradeSEC
S-8 · Registration statement for employee plansFeb 29, 2024Offer documentSEC
10-K · Annual reportFeb 29, 2024Annual reportSEC

This page holds 200 of 444 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from 4D Molecular Therapeutics, Inc.’s releases · as of Nov 10, 2026

Common shares
55,244,211
Fully diluted
55,266,011

Fully diluted

LineSharesAs of
Common shares55,244,211
Options and RSUs21,800Nov 10, 2026

Warrants and options

Lot
RSUs · expiry not stated

Share count over time

CountShares
Nov 22, 202655,244,211

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Janus Henderson5.73MUS$81.9MSep 30, 2026
Ra Capital Management, L.P.5.05MUS$72.3MSep 30, 2026
BlackRock4.72MUS$67.6MSep 30, 2026
Goldman Sachs3.93MUS$56.2MSep 30, 2026
Vanguard3.05MUS$43.7MSep 30, 2026
Novo Holdings A/S3MUS$42.9MSep 30, 2026
Bvf Inc2.88MUS$41.2MSep 30, 2026
State Street2.47MUS$35.3MSep 30, 2026
T. Rowe Price2.32MUS$33.2MSep 30, 2026
Adage Capital Partners Gp, L.L.C.2.29MUS$32.8MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Trails Edge Capital Partners, LP2.23MUS$31.9MSep 30, 2026
Armistice Capital, LLC1.95MUS$27.9MSep 30, 2026
Bank of America1.53MUS$22MSep 30, 2026
Geode Capital1.18MUS$17MSep 30, 2026
Morgan Stanley1.09MUS$15.6MSep 30, 2026
Evergreen Quality Fund GP, Ltd.951KUS$13.6MSep 30, 2026
Dimensional787KUS$11.3MSep 30, 2026
Parkman Healthcare Partners LLC772KUS$11MSep 30, 2026
Catalio Capital Management, LP685KUS$9.8MSep 30, 2026
DWS546KUS$7.81MSep 30, 2026
Northern Trust540KUS$7.73MSep 30, 2026
Acuta Capital Partners, LLC535KUS$7.66MSep 30, 2026
Schwab439KUS$6.28MSep 30, 2026
Diadema Partners LP421KUS$6.03MSep 30, 2026
Renaissance Technologies412KUS$5.89MSep 30, 2026
JPMorgan393KUS$5.69MSep 30, 2026
Nuveen391KUS$5.59MSep 30, 2026
Opaleye Management Inc.334KUS$4.79MSep 30, 2026
Fidelity312KUS$4.46MSep 30, 2026
Hrt Financial LP306KUS$4.38MSep 30, 2026
Burkehill Global Management, LP275KUS$3.94MSep 30, 2026
Susquehanna266KUS$3.81MSep 30, 2026
Invesco260KUS$3.72MSep 30, 2026
Raymond James Financial Inc242KUS$3.46MSep 30, 2026
Brevan Howard Capital Management LP204KUS$2.92MSep 30, 2026
ArrowMark Colorado Holdings LLC203KUS$2.9MSep 30, 2026
Woodline Partners LP200KUS$2.86MSep 30, 2026
Voya Investment Management LLC192KUS$2.75MSep 30, 2026
Barclays180KUS$2.57MSep 30, 2026
Propel Bio Management, LLC179KUS$2.56MSep 30, 2026
Federated Hermes, Inc.177KUS$2.53MSep 30, 2026
Schonfeld Strategic Advisors LLC175KUS$2.51MSep 30, 2026
Jane Street171KUS$2.45MSep 30, 2026
Wellington163KUS$2.33MSep 30, 2026
Citadel154KUS$2.21MSep 30, 2026
BNY153KUS$2.18MSep 30, 2026
Greenland Capital Management LP152KUS$2.17MSep 30, 2026
Ikarian Capital, LLC150KUS$2.15MSep 30, 2026
Trexquant Investment LP148KUS$2.12MSep 30, 2026
Perigon Wealth Management, LLC146KUS$2.09MSep 30, 2026

This page holds 50 of 160 holders. Open Shareholders

Funds

HolderSharesValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF1.61MUS$21.4MJun 30, 2026
Vanguard Total Stock Market Index Fund1.59MUS$21.1MJun 30, 2026
iShares Russell 2000 ETF1.18MUS$15.7MJun 30, 2026
Janus Henderson Global Life Sciences Fund788KUS$10.5MJun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.682KUS$9.07MJun 30, 2026
Fidelity Small Cap Index Fund502KUS$5.11MJul 31, 2026
Vanguard Extended Market Index Fund460KUS$6.12MJun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.455KUS$6.06MJun 30, 2026
iShares Russell 2000 Value ETF413KUS$5.49MJun 30, 2026
Nuveen Quant Small Cap Equity Fund389KUS$3.96MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
T. Rowe Price Institutional Small-Cap Stock Fund368KUS$4.9MJun 30, 2026
iShares Biotechnology ETF329KUS$4.38MJun 30, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF276KUS$3.67MJun 30, 2026
Vanguard Russell 2000 Index Fund227KUS$2.25MMay 31, 2026
Federated Hermes MDT Small Cap Core Fund209KUS$2.13MJul 31, 2026
Fidelity Extended Market Index Fund203KUS$2.01MMay 31, 2026
Schwab U.S. Small-Cap ETF184KUS$1.82MMay 31, 2026
Dimensional U.S. Small Cap ETF171KUS$1.74MJul 31, 2026
Small Cap Value Fund159KUS$2.11MJun 30, 2026
iShares Micro-Cap ETF151KUS$2.01MJun 30, 2026
Vanguard U.S. Momentum Factor ETF151KUS$1.49MMay 31, 2026
Invesco Dorsey Wright SmallCap Momentum ETF150KUS$1.49MMay 31, 2026
BlackRock Advantage Small Cap Core Fund139KUS$1.38MMay 29, 2026
U.S. Micro Cap Portfolio128KUS$1.3MJul 31, 2026
Vanguard Health Care Index Fund128KUS$1.27MMay 31, 2026
BlackRock Health Sciences Opportunities Portfolio126KUS$1.25MMay 29, 2026
U.S. Small Cap Portfolio119KUS$1.22MJul 31, 2026
Schwab Small-Cap Index Fund111KUS$1.13MJul 31, 2026
Avantis U.S. Small Cap Equity ETF99,652US$988KMay 31, 2026
Master Small Cap Index Series86,878US$1.16MJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF86,475US$880KJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF82,924US$1.1MJun 30, 2026
Fidelity Total Market Index Fund76,729US$760KMay 31, 2026
Fidelity Small Cap Value Index Fund64,016US$851KJun 30, 2026
Nuveen Small Cap Blend Index Fund60,927US$620KJul 31, 2026
Fidelity Series Total Market Index Fund59,387US$589KMay 31, 2026
Vanguard Strategic Small-Cap Equity Fund54,884US$730KJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares54,661US$556KJul 31, 2026
JPMorgan U.S. Small Company Fund53,185US$707KJun 30, 2026
Bridge Builder Tax Managed Small/Mid Cap Fund51,056US$679KJun 30, 2026
EQ/2000 Managed Volatility Portfolio50,241US$668KJun 30, 2026
Fidelity Enhanced Small Cap Core ETF50,196US$668KJun 30, 2026
Voya Small Company Portfolio48,865US$650KJun 30, 2026
Dimensional U.S. Core Equity 2 ETF44,264US$451KJul 31, 2026
Voya MI Dynamic Small Cap Fund43,888US$435KMay 31, 2026
U.S. Core Equity 2 Portfolio40,842US$416KJul 31, 2026
Invesco BuyBack AchieversTM ETF39,203US$399KJul 31, 2026
Virtus Biotech Clinical Trials Etf35,199US$358KJul 31, 2026
Vanguard Russell 2000 Value Index Fund35,199US$349KMay 31, 2026
EQ/Small Company Index Portfolio33,010US$439KJun 30, 2026

This page holds 50 of 168 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Bizily Scott
Officer: Chief Legal Officer
Sale1,635USD 12.84US$20,993Oct 16, 2026
Kirn David
Director, Officer: See Remarks
Sale58,061USD 12.92US$750KOct 5, 2026
Kirn David
Director, Officer: See Remarks
Sale272USD 13.61US$3,702Oct 5, 2026
Bizily Scott
Officer: Chief Legal Officer
Sale1,635USD 13.65US$22,318Sep 16, 2026
Kirn David
Director, Officer: See Remarks
Sale58,333USD 13.90US$811KSep 14, 2026
Bizily Scott
Officer: Chief Legal Officer
Sale584USD 14.00US$8,176Sep 1, 2026
Kirn David
Director, Officer: See Remarks
Sale43,149USD 15.36US$663KAug 19, 2026
Kirn David
Director, Officer: See Remarks
Sale25,927USD 16.42US$426KAug 19, 2026
Bizily Scott
Officer: Chief Legal Officer
Sale1,635USD 12.20US$19,947Aug 17, 2026
Bizily Scott
Officer: Chief Legal Officer
Sale1,635USD 12.00US$19,620Aug 13, 2026
All 19 trades
TradeTradeSharesPriceValueDate
Kirn David
Director, Officer: See Remarks
Sale26,842USD 10.23US$275KAug 4, 2026
Kirn David
Director, Officer: See Remarks
Sale12,415USD 10.05US$125KAug 3, 2026
Kirn David
Director, Officer: See Remarks
Sale15,283USD 12.01US$184KJul 10, 2026
Kirn David
Director, Officer: See Remarks
Sale442USD 12.84US$5,675Jul 10, 2026
Kirn David
Director, Officer: See Remarks
Sale42,608USD 12.87US$548KJul 9, 2026
Bizily Scott
Officer: Chief Legal Officer
Sale6,566USD 14.00US$91,924Jun 30, 2026
Bizily Scott
Officer: Chief Legal Officer
Sale9,810USD 12.00US$118KJun 23, 2026
Kirn David
Director, Officer: See Remarks
Sale114,746USD 10.47US$1.2MJun 22, 2026
Kirn David
Director, Officer: See Remarks
Sale1,922USD 10.02US$19,258Jun 1, 2026

Big stakes

StakeStakeSharesDateFiling
Janus Henderson Group PLC10.30%5.25MMar 31, 2026Schedule 13G
BVF PARTNERS L P/IL9.99%5.81MSep 30, 2026Schedule 13G
Ra Capital Management, L.P.9.90%5.11MMar 31, 2026Schedule 13G
Goldman Sachs Group Inc7.50%4.29MDec 31, 2025Schedule 13G
BlackRock, Inc.6.60%3.06MSep 30, 2025Schedule 13G
Novo Holdings A/S5.40%3MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Shawn Tomasello
Other companies: Cabaletta Bio, Inc. (Director · Since at least Jul 21, 2023); Kalaris Therapeutics, Inc. (Director · Mar 29, 2022 – Jun 6, 2024 · Past); Gamida Cell Ltd (Director · Jan 1, 2022 – Jan 31, 2024 · Past); UroGen Pharma Ltd. (Director · Jun 7, 2021 – Jun 7, 2021 · Past); Tcr2 Therapeutics Inc (Director · Feb 3, 2021 – Jun 1, 2023 · Past)
Director · Since at least Dec 10, 2020
August Moretti
Other companies: Vivani Medical, Inc. (Member of the Board · Since at least Jun 24, 2026); Cibus, Inc. (Director · Since at least Nov 18, 2024); Depomed Inc (Chief Financial Officer & SVP · Jan 3, 2012 – Mar 31, 2018 · Past); Alexza Pharmaceuticals Inc (Former SVP, CFO, GC & Sec · Mar 8, 2006 – Dec 31, 2011 · Past)
Chief Financial Officer · Dec 10, 2020 – May 15, 2023 · Past
Susannah Gray
Other companies: AnaptysBio, Inc. (Director · Since at least Mar 26, 2026); Maravai LifeSciences Holdings, Inc. (Director · Since at least May 23, 2024); Theravance Biopharma, Inc. (Director · Since at least May 8, 2024); Morphic Holding Inc (Director · Jun 4, 2024 – Aug 16, 2024 · Past)
Director · Since at least May 21, 2024
John F. Milligan
Other companies: Kailera Therapeutics, Inc. (Board Chair · Since at least Apr 16, 2026); Pacific Biosciences of California, Inc. (Chairman of the Board · Since at least Jul 17, 2013); Gilead Sciences, Inc. (President and CEO, Director · Nov 7, 2013 – Nov 27, 2018 · Past)
Executive Chairman · Since at least Dec 10, 2020
Kristian Humer
Other companies: Foghorn Therapeutics Inc. (Chief Financial Officer · Since at least Apr 16, 2024); Sensei Biotherapeutics, Inc. (Director · Jul 30, 2021 – May 21, 2025 · Past); Viridian Therapeutics, Inc. (CFO and CBO · Jul 26, 2021 – Feb 8, 2023 · Past)
Chief Financial Officer · Since at least Dec 9, 2025
Nancy Miller-Rich
Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Jan 13, 2020); Kadmon Holdings Inc (Director · Aug 13, 2020 – Nov 9, 2021 · Past); Intercept Pharmaceuticals Inc (Director · Apr 24, 2018 – Nov 8, 2023 · Past)
Director · Since at least Dec 10, 2020
Glenn P. Sblendorio
Other companies: Mineralys Therapeutics, Inc. (Chairman · Since at least Feb 19, 2026); Amicus Therapeutics Inc (Director · Since at least Jun 5, 2025)
Board Member · Since at least Jan 5, 2026
Charles Theuer
Other companies: Oncternal Therapeutics Inc (Director · Jun 7, 2019 – Jun 20, 2024 · Past)
Director · Since at least Dec 10, 2020
Christopher Paul Simms
Other companies: IVERIC bio Inc (SVP, Chief Commercial Officer · Aug 2, 2021 – Jul 11, 2023 · Past)
See Remarks · Since at least Dec 9, 2025
Jacob Chacko
Other companies: ORIC Pharmaceuticals, Inc. (PRESIDENT AND CEO, Director · Since at least Feb 1, 2021)
Director · Since at least Dec 10, 2020
All 20 people
PersonSeat
Ashoo GuptaVP, Finance and Controller · Since at least Sep 30, 2025
Chris SimmsChief Commercial & Business Officer · Since at least Mar 18, 2026
David KirnChief Executive Officer, President, and Co-Founder · Since at least Dec 10, 2020
Dhaval DesaiChief Development Officer · Since at least Sep 2, 2025
Julie ClarkChief Medical Officer · Since at least Jun 29, 2026
Katy BarglowChief Technical Officer · Since at least Mar 18, 2026
Kim MaplestoneChief Clinical Operations Officer · Since at least Mar 18, 2026
Robert Young KimChief Medical Officer · Mar 24, 2023 – Mar 6, 2025 · Past
Scott BizilyChief Legal Officer · Since at least Mar 21, 2022
Theresa JankeChief of Staff, Co-Founder · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about 4D Molecular Therapeutics, Inc.